Emily Ostrowski, MD
Family Medicine · Lithia, FLNPI 1043212483
Payments from drug & device makers
Across 279 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- AbbVie$514
- AstraZeneca$481
- Exact Sciences$288
- Pfizer$286
- plus $1K from 27 others
What the payments were for
- Food & beverage$5,199100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 65 | $1,174 |
| Lilly USA, LLC | 58 | $1,007 |
| AbbVie(2 entities) | 26 | $514 |
| AstraZeneca | 26 | $481 |
| Exact Sciences | 13 | $288 |
| Pfizer | 15 | $286 |
| Dynavax Technologies Corporation | 7 | $157 |
| Amgen | 8 | $140 |
| Boehringer Ingelheim | 8 | $140 |
| Eisai Inc. | 6 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $118 |
| IBSA Pharma Inc. | 5 | $76 |
| GSK | 4 | $71 |
| Phadia US Inc. | 4 | $69 |
| Amarin Pharma, Inc. | 3 | $62 |
| Merck | 3 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Astellas Pharma US Inc | 2 | $34 |
| Nevro Corp. | 1 | $32 |
| Si-bone, Inc. | 2 | $31 |
| Bayer | 1 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $30 |
| Novartis | 1 | $23 |
| Shield Therapeutics Inc | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Lucid Diagnostics Inc. | 1 | $18 |
| Angiodynamics, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Painteq LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$5,199 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $72,556 |
| EliquisApixaban | 27 | $39,320 |
| JardianceEmpagliflozin | 42 | $35,776 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,728 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $6,520 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 11 | $3,425 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,361 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,037 |
| Atorvastatin Calcium | 219 | $1,980 |
| Metoprolol Succinate | 82 | $1,672 |
| Gabapentin | 66 | $1,663 |
| Levothyroxine Sodium | 163 | $1,627 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $1,497 |
| Rosuvastatin Calcium | 133 | $1,197 |
| Potassium Citrate ErPotassium Citrate | 17 | $1,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,174 | $72,55666 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $140 | $42,29653 claims |
| PfizerEliquis | $286 | $39,32027 claims |
| GSKTrelegy Ellipta | $71 | $11,72814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Lithia
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.